Attorney Docket: P-108-US2 Customer No.: 27,038

Page 12

REMARKS

1. Status of the Claims

Claims 12-19 and 24-27 have been canceled. Claims 1 and 28 have been amended. Upon entry of the above amendment, Claims 1-11, 20-23 and 28-33 will be pending for examination.

2. Amendments to the Specification

The application has been amended on page 1, lines 6-8 to correct the section heading and to claim priority for the instant application as a divisional application of U.S. Serial No. 10/050,696, filed January 15, 2002, now allowed.

The parent application was subject to a restriction requirement and an election of species requirement. The present application is directed to subject matter which was excluded by the species restriction in the parent application.

3. Amendments to the Claims

Claim 1 has been amended to define X as a direct bond and R₃ as an N-linked heteroaryl or an N-linked heterocycle. Support for this amendment can be found in original Claim 1, and on page 36, lines 1-4 of the specification as filed.

Claim 28 has been amended to claim specific structures found in Tables I-XI. Support for this amendment can be found in the specification as filed on pages 15-16, (compound nos. 30-36); pages 18-19, (compound nos. 47-53); and page 22 (compound nos. 92).

No new matter has been added. Entry of the above amendments is respectfully requested. Applicants respectfully request further processing of this application.

Attorney Docket: <u>P-108-US2</u> Customer No.: <u>27,038</u>

Page 13

Should there be any issues that can be resolved by telephone, the Examiner is invited to telephone the undersigned Agent for Applicants at (650) 808-6144.

Respectfully submitted,

Date: September // , 2003

THERAVANCE, INC. Attn: Legal Dept. 901 Gateway Boulevard

South San Francisco, CA 94080

Tel: (650) 808-6000 Fax: (650) 808-6078